Literature DB >> 3142350

In vitro activity of PD 127,391, an enhanced-spectrum quinolone.

R Wise1, J P Ashby, J M Andrews.   

Abstract

The in vitro activity of PD 127,391, a dihalogenated quinolone, was compared with those of ofloxacin, ciprofloxacin, nalidixic acid, gentamicin, and cefuroxime against 525 recent isolates and well-characterized antimicrobial agent-resistant strains. The MICs of PD 127,391 against 90% of members of the family Enterobacteriaceae, Bacteroides fragilis, Haemophilus influenzae, Neisseria sp., and Streptococcus pneumoniae were less than or equal to 0.12 microgram/ml. Some 90% of Pseudomonas aeruginosa and staphylococci were susceptible to 0.25 micrograms of PD 127,391 per ml. Against most strains, PD 127,391 was 2- to 8-fold more active than ciprofloxacin, but it was 64-fold more active than ciprofloxacin against B. fragilis. Strains of members of the family Enterobacteriaceae which were resistant to nalidixic acid were less susceptible to all of the quinolones tested, including PD 127,391. The MIC and minimum lethal concentration of PD 127,391 against three strains of Chlamydia trachomatis were each 0.06 microgram/ml, and the MIC against 90% of 21 strains of Mycobacterium tuberculosis was 1 microgram/ml. PD 127,391 was less active at pH 5, its maximal activity being at pH 7 to 8. The presence of urine at pH 5.9 decreased the bactericidal activity. The protein binding of PD 127,391 was 2 to 7%, and serum had little effect on activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142350      PMCID: PMC172387          DOI: 10.1128/AAC.32.8.1251

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis.

Authors:  J M Webberley; R S Matthews; J M Andrews; R Wise
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

Review 2.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

Review 3.  Mechanisms of action of and resistance to ciprofloxacin.

Authors:  D C Hooper; J S Wolfson; E Y Ng; M N Swartz
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

4.  Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

Authors:  S Inoue; T Ohue; J Yamagishi; S Nakamura; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

5.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections.

Authors:  C M Wollschlager; S Raoof; F A Khan; J J Guarneri; V LaBombardi; Q Afzal
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

8.  Treatment of nongonococcal urethritis with ciprofloxacin.

Authors:  I W Fong; W Linton; M Simbul; R Thorup; B McLaughlin; V Rahm; P A Quinn
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

9.  In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.

Authors:  R Wise; J M Andrews; G Danks
Journal:  J Antimicrob Chemother       Date:  1984-03       Impact factor: 5.790

10.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

View more
  28 in total

1.  In vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian national survey from 1983 to 1985.

Authors:  P Van der Auwera; C Godard; C Denis; S De Maeyer; R Vanhoof
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.

Authors:  D Gargallo-Viola; M Esteve; S Llovera; X Roca; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 4.  The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

5.  In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.

Authors:  D M Sedlock; R A Dobson; D M Deuel; G Y Lesher; J B Rake
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

6.  Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.

Authors:  R Wise; S Jones; I Das; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

7.  Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; M Esteve; M Moros; R Coll; M A Xicota; C de Andres; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

8.  Value of new quinolones in the treatment and prophylaxis of infectious diseases: introductory remarks.

Authors:  J S Wolfson; B E Murray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

9.  Comparative in vitro activities of new quinolones against coryneform bacteria.

Authors:  L Martínez-Martínez; A I Suárez; M C Ortega; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Mechanism of differential activities of ofloxacin enantiomers.

Authors:  I Morrissey; K Hoshino; K Sato; A Yoshida; I Hayakawa; M G Bures; L L Shen
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.